The clinical trial landscape for chronic lymphocytic leukemia (CLL) shows a robust global effort to advance treatment options and understand the disease, according to a report.
Contract research organization Novotech has published the research report, entitled Chronic Lymphocytic Leukemia (CLL) - Global Clinical Trial Landscape.
The report reveals that, since 2019, more than 1,000 clinical trials have been started worldwide, with North America leading at 37% of these studies, followed closely by the Asia-Pacific region at 34%, Europe at 20%, and the rest of the world with 8%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze